By Sneha S K June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to ...
DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives ...
DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line ...
The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...
A new study presented at the American Diabetes Association found that Dexcom’s G7 continuous glucose monitor significantly ...
DexCom (NASDAQ:DXCM) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...
First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required ...
MADRID--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM), announced today the Dexcom G6 CGM System has received the CE Mark for use during pregnancy in ...